Par Drugs and Chemicals Limited AI Stock Analysis
Want to see IN:PAR full AI Analyst Report?
Par Drugs and Chemicals Limited (PAR) AI Stock Analysis
Par Drugs and Chemicals Limited
(NSE:PAR)
Par Drugs and Chemicals achieves a solid overall score heavily driven by its exceptionally strong, debt-free balance sheet, robust free cash flow generation, and an attractive valuation multiple. The main headwinds preventing a higher score are ongoing margin compression impacting profitability and weak short-term technical momentum, though heavily oversold technical indicators suggest downward pressure may be exhausting.
Par Drugs and Chemicals Limited (PAR) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 1.38B
- Dividend Yield
- ―
- Average Volume (3M)
- 64.64K
- Price to Earnings (P/E)
- 10.6
- Beta (1Y)
- 0.71
- Revenue Growth
- 9.40%
- EPS Growth
- 34.12%
- Country
- India
- Employees
- 118
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Par Drugs and Chemicals Limited Business Overview & Revenue Model
Company Description
Par Drugs and Chemicals Limited is an Indian enterprise that focuses on the creation, production, and sale of active pharmaceutical ingredients (APIs) and specialized chemicals. Its comprehensive product line features a diverse array of compounds, su...
How the Company Makes Money
null
Par Drugs and Chemicals Limited Financial Statement Overview
Summary
The company maintains a pristine, debt-free balance sheet and excellent cash flow conversion capabilities. However, recent gross and operating margin compression slightly pressures overall return on equity despite steady top-line revenue growth.
Income Statement
65PositiveBalance Sheet
92Very PositiveCash Flow
85Very Positive| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.08B | 1.04B | 1.01B | 956.40M | 950.95M | 746.15M |
| Gross Profit | 497.08M | 504.71M | 617.86M | 609.88M | 286.90M | 173.68M |
| EBITDA | 183.88M | 211.32M | 195.01M | 229.53M | 184.46M | 163.61M |
| Net Income | 129.91M | 131.09M | 133.58M | 145.01M | 113.34M | 92.13M |
Balance Sheet | ||||||
| Total Assets | 1.39B | 1.29B | 1.19B | 1.02B | 888.68M | 786.90M |
| Cash, Cash Equivalents and Short-Term Investments | 363.62M | 418.43M | 275.77M | 366.54M | 222.43M | 162.06M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 194.08M | 172.28M | 204.15M | 159.79M | 176.30M | 188.13M |
| Stockholders Equity | 1.19B | 1.12B | 989.75M | 856.32M | 712.38M | 598.77M |
Cash Flow | ||||||
| Free Cash Flow | 0 | 144.71M | 149.34M | 141.69M | 57.44M | 44.13M |
| Operating Cash Flow | 0 | 164.32M | 161.60M | 202.49M | 133.77M | 76.15M |
| Investing Cash Flow | 0 | -21.66M | -252.37M | -58.38M | -73.38M | -30.18M |
| Financing Cash Flow | 0 | 0 | 0 | 0 | -24.00K | -95.54M |
Par Drugs and Chemicals Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:PAR, the sentiment is Negative. The current price of 112.06 is below the 20-day moving average (MA) of 112.84, below the 50-day MA of 120.15, and above the 200-day MA of 101.43, indicating a neutral trend. The MACD of -0.62 indicates Negative momentum. The RSI at 46.48 is Neutral, neither overbought nor oversold. The STOCH value of 32.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:PAR.
Par Drugs and Chemicals Limited Peers Comparison
Overall Rating
IN:PAR71Outperform
IN:BROOKS61Neutral
IN:BALPHARMA58Neutral
IN:BIOFILCHEM58Neutral
IN:ALPA54Neutral
IN:VIVIMEDLAB40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 71Outperform | INR 1.40B | 10.61 | ― | ― | 9.40% | 34.12% | |
| 61Neutral | INR 1.99B | 2.71 | ― | ― | -14.88% | 431.30% | |
| 58Neutral | INR 1.35B | 16.71 | ― | 1.43% | 18.79% | -2.58% | |
| 58Neutral | INR 483.49M | 99.32 | ― | ― | 9.31% | -82.71% | |
| 54Neutral | INR 1.06B | 66.56 | ― | ― | 3.51% | -87.03% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 40Underperform | INR 456.03M | -0.23 | ― | ― | -39.80% | -452.04% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:PAR | Par Drugs and Chemicals Limited | 112.06 | 20.46 | 22.34% | |
| IN:ALPA | Alpa Laboratories Limited | 49.97 | -27.16 | -35.21% | |
| IN:BALPHARMA | Bal Pharma Limited | 83.50 | 8.84 | 11.84% | |
| IN:BIOFILCHEM | Biofil Chemicals & Pharmaceuticals Ltd. | 30.72 | -7.28 | -19.16% | |
| IN:BROOKS | Brooks Laboratories Limited | 67.29 | -28.91 | -30.05% | |
| IN:VIVIMEDLAB | Vivimed Labs Limited | 5.50 | 0.60 | 12.24% |
Par Drugs and Chemicals Limited Corporate Events
Par Drugs and Chemicals’ 27th AGM Clears All Resolutions with Majority Support
Par Drugs and Chemicals Limited held its 27th Annual General Meeting on 26 September 2026 in Vadodara, Gujarat, providing shareholders with remote e-voting and on-site ballot options in line with the Companies Act and SEBI listing regulations. An ind...
Par Drugs and Chemicals Publishes AGM and E‑Voting Notice in Newspapers
Par Drugs and Chemicals Limited has published statutory newspaper advertisements announcing the notice and e‑voting details for its 27th Annual General Meeting. The communication, released in The Economic Times and Navgujarat Samay, is part of the co...
Par Drugs and Chemicals Flags Unclaimed Dividend Shares for Transfer to IEPF
Par Drugs and Chemicals Limited has notified shareholders and the stock exchange that certain equity shares are liable to be transferred to the Investor Education and Protection Fund, as required under the IEPF Authority Rules, 2016. The move affects...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 17, 2026
